This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology (ALGN) poised to gain on continued strength in all geographies in Q2.
Top Stock Reports for Wells Fargo, IBM & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT).
Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.
Housing Starts/Permits Disappoint; MS, USB and ABT Beat
by Mark Vickery
Morgan Stanley, U.S. Bank and Abbott all beat expectations, but new Housing Starts and Permits numbers were far below expectations.
Abbott (ABT) Beats on Earnings and Revenues in Q2
by Zacks Equity Research
Abbott (ABT) gains ground on new product launches and solid overall growth and delivers strong Q2 results.
These Companies are Earnings All-Stars
by Tracey Ryniec
It's not easy to beat on earnings nearly every quarter but these 5 companies are doing just that. Can they keep up their winning streaks?
Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.
Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to gain on continued growth in Medical Devices business in Q2.
Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?
by Zacks Equity Research
Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.
Here's Why AbbVie Stock is Good for Your Portfolio's Health
by Zacks Equity Research
Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.
The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
Top Stock Reports for Facebook, Amgen & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Amgen (AMGN), and Abbott (ABT).
Tap Cardiovascular Devices Market Boom With These 3 Stocks
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing cardiovascular devices market.
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
Boston Scientific Up on Possible Takeover Bid by Stryker
by Zacks Equity Research
Even if Boston Scientific's (BSX) position remains indefinite on a possible sell-off rumor, the company's strategic stance on this might however, swing in its favor for winning a competitive marketing edge.
Bio-Rad Banks on Solid Global Scenario, Competition Rife
by Zacks Equity Research
Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.
Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.
by Zacks Equity Research
Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.
The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman
Abbott Presents Positive Data for AMPLATZER Amulet Device
by Zacks Equity Research
Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.
Abbott Presents Positive Study Results for Tendyne Device
by Zacks Equity Research
Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.
Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing
by Zacks Equity Research
Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.
Cardiovascular Systems Rides on New Products Amid Tight Race
by Zacks Equity Research
Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.
Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?
by Zacks Equity Research
Both Merck and Pfizer reported upbeat first-quarter results on May 1
Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Universal Health (UHS) posts a solid Q1 driven by higher revenues.